Intrauterine Growth Restriction (IUGR) / Fetal Growth Restriction (FGR)

Definition

• SGA (Small for Gestational Age): birth weight <10th percentile - a population-based statistical label
• FGR: failure to reach genetic growth potential - a pathophysiologic process; SGA is used as a surrogate but is not synonymous

"FGR is not a homogeneous entity, and different phenotypes of FGR behave differently." - Creasy & Resnik's Maternal-Fetal Medicine

Classification

1. By Pattern (Symmetric vs. Asymmetric)

2. By Gestational Age at Diagnosis (Box 44.1, Creasy & Resnik)

• Early-onset FGR (<32 weeks) has a strong association with preeclampsia, carries high morbidity/mortality, and shows the classic Doppler deterioration sequence. 94% of perinatal deaths in FGR with abnormal UA Doppler occur at delivery <29 weeks.
• Late-onset FGR (≥32 weeks) is more common but carries lower mortality; Doppler findings may be subtler.

Etiology & Risk Factors

Maternal Factors (most common category)

• Vascular disease: chronic hypertension, preeclampsia (most important)
• Antiphospholipid syndrome, SLE, other autoimmune disease
• Pregestational diabetes with vasculopathy
• Chronic renal insufficiency
• Smoking, alcohol, illicit drugs (cocaine, narcotics) - avoidable causes
• Malnutrition, inflammatory bowel disease
• Teratogenic medications: beta-blockers, phenytoin, warfarin, valproic acid, cyclophosphamide
• High altitude (reduced O2)
• Hemoglobinopathies, cyanotic heart disease

Fetal Factors

• Chromosomal abnormalities: trisomy 13, 18, 21, triploidy
• Structural malformations: congenital heart disease, gastroschisis
• TORCH infections: CMV, rubella, toxoplasmosis, syphilis, HIV, varicella, malaria
• Multiple gestation (risk increases: twin < triplet < quadruplet)

Placental Factors

• Placenta previa, placental abruption/infarction
• Velamentous or marginal cord insertion, single umbilical artery
• Placental hemangioma/chorioangioma
• Selective FGR in monochorionic twins

When cause is intrinsic to the fetus (chromosomal/infectious), growth restriction is symmetric. With placental/maternal causes, it is asymmetric (brain sparing).

Pathophysiology

1. Reduced umbilical blood flow per kg fetal weight - decreased terminal villi growth reduces umbilical capillary bed expansion; umbilical pulsatility index (PI) rises above normal
2. Reduced vasosyncytial membrane production - greater fraction of O2 uptake occurs by diffusion across thick oxygen-consuming placental barrier; placental O2 permeability is abnormally low
3. Reduced placental glucose permeability - decreased transplacental glucose transfer

• Enlarges transplacental PO2 gradient to draw more O2 into fetal circulation
• Slows fetal metabolic demands by reducing growth rate

Diagnosis

Screening

• Fundal height (FH) measurement: between 18-40 weeks, FH in cm approximates gestational age. A single measurement at 32-34 weeks has 85% sensitivity and 96% specificity for FGR detection. However, maternal obesity significantly affects accuracy.

Ultrasound Biometry (gold standard)

• AC is the most sensitive single measurement for FGR
• EFW <10th percentile is the standard threshold
• Serial measurements every 2-3 weeks assess growth velocity (more informative than a single measurement)

Doppler Velocimetry (most important management tool)

"Umbilical artery Doppler findings strongly correlate with fetal growth restriction and critical fetal and neonatal outcomes, with outcomes progressively worsening in association with reduction, loss, and reversal of diastolic flow." - Creasy & Resnik, Block 7

• Absent a-wave: concerning
• Reversed a-wave: extremely ominous - associated with imminent fetal demise, indicates venous hypertension and right heart failure

FGR Staging System (Creasy & Resnik, Table 44.1)

Sequence of Deterioration in FGR

1. UA PI rises (elevated placental resistance)
2. Cerebroplacental ratio shifts - cerebral redistribution/brain sparing (MCA diastolic velocity increases)
3. UA AEDF - oligohydramnios becomes more common
4. NST becomes flat/non-reactive
5. DV a-wave becomes absent
6. UA REDF (occurs in ~20% of severe FGR)
7. DV a-wave reverses
8. BPP becomes overtly abnormal (loss of breathing movements, tone, movements)
9. Fetal death if not delivered

Antenatal Surveillance

• Serial growth ultrasound every 2-3 weeks
• Amniotic fluid index (AFI) assessment - oligohydramnios is a sign of compromise
• Non-stress test (NST) twice weekly
• Biophysical profile (BPP) - used when NST is non-reactive
• Umbilical artery Doppler velocimetry weekly - the most valuable single tool

"The rate of perinatal death is reduced by as much as 29% when umbilical artery Doppler velocimetry is added to standard antepartum testing." - Swanson's Family Medicine Review

Delivery Timing

• Antenatal corticosteroids (betamethasone) indicated for delivery between 24-34 weeks
• Mode of delivery must be individualized - IUGR fetuses have higher risk of fetal heart rate abnormalities, meconium passage, and acidemia; proceed to cesarean if fetal status deteriorates or cervix is unfavorable

Neonatal Complications

• Perinatal asphyxia, low Apgar scores
• Hypoglycemia (depleted glycogen stores)
• Hypothermia (reduced subcutaneous fat)
• Hyperbilirubinemia (polycythemia)
• Necrotizing enterocolitis (NEC)
• Intraventricular hemorrhage (IVH)
• Respiratory distress syndrome
• Sepsis, seizures
• Intrauterine fetal demise (stillbirth) - risk is 1.5% at <10th percentile, increases to 2.5% at <5th percentile

Long-Term Consequences ("Barker Hypothesis" / Developmental Origins of Disease)

• Hypertension, coronary artery disease
• Type 2 diabetes, insulin resistance
• Obesity ("thrifty phenotype" paradox)
• Neurodevelopmental delays

Prevention

• Low-dose aspirin (starting <16 weeks) in high-risk patients (prior FGR, preeclampsia, antiphospholipid syndrome) reduces early preterm delivery <34 weeks (RR 0.75)
• Smoking cessation
• Optimizing management of maternal medical conditions (hypertension, diabetes, lupus)
• No proven benefit from bed rest, oxygen supplementation, or nutritional supplementation beyond correcting specific deficiencies

Mechanism of Action of L-Arginine in IUGR

The Core Pathway: L-Arginine → Nitric Oxide → Vasodilation

L-Arginine  ──(eNOS + cofactors)──►  Nitric Oxide (NO) + L-Citrulline
                                            │
                                            ▼
                              Vascular smooth muscle relaxation
                                            │
                                            ▼
                        Uteroplacental vasodilation → ↑ placental perfusion

• L-Arginine as substrate
• Cofactors: tetrahydrobiopterin (BH4), flavin adenine dinucleotide (FAD), flavin mononucleotide (FMN), calmodulin, iron protoporphyrin IX

"Vascular NO is mainly produced from L-arginine by endothelial NOS (eNOS). Production of NO from L-arginine by NOS also requires cofactors including tetrahydrobiopterin (BH4), FAD, FMN, calmodulin, and iron protoporphyrin IX." - Fuster & Hurst's The Heart, 15th Ed.

Why NO Is Reduced in IUGR / Placental Insufficiency

"The placenta directly or indirectly produces substances that alter endothelial function and induces uncoupling of the nitric oxide synthase leading to deficient nitric oxide production but with excess nitrative stress." - Creasy & Resnik's Maternal-Fetal Medicine

Mechanisms by Which L-Arginine Supplementation Helps

1. Restores NO Substrate Availability

• Increases plasma L-arginine levels
• Provides eNOS with adequate substrate to generate NO despite unfavorable conditions
• Raises circulating NO metabolites (nitrites/nitrates) - confirmed in the 2022 meta-analysis (SMD +0.71, 95% CI 0.45-0.97, I² = 0%)

2. Uteroplacental Vasodilation

• Uterine artery blood flow
• Intervillous space perfusion
• Umbilical artery pulsatility index (may improve Doppler findings)

3. Fetal Vasodilation & Growth Promotion

• Reduce fetoplacental vascular resistance
• Improve umbilical blood flow per kg fetal weight
• Enhance nutrient and oxygen delivery to fetal tissues

4. Angiogenesis & Placental Development

5. Anti-Oxidant Effect

6. Additional Roles Beyond NO

• L-arginine is a precursor to polyamines (putrescine, spermidine, spermine) - essential for cell proliferation and fetal growth
• Precursor to creatine - important for energy metabolism in fetal muscle
• Precursor to proline - needed for collagen synthesis and fetal connective tissue

Clinical Evidence Summary

2022 Meta-Analysis (Xu et al., PMID 35667267 - Systematic Review + Meta-Analysis, Clin Nutr)

• Increased plasma NO concentrations (SMD +0.71, 95% CI 0.45-0.97; I² = 0%) - confirming the mechanistic target
• Increased birth weight by ~134 g (WMD +134.00 g, 95% CI 43.53-224.46; I² = 42.4%)
• Reduced SGA risk by 54% (RR 0.46, 95% CI 0.25-0.88; I² = 0%)
• No significant effect on gestational age in IUGR mothers
• Intravenous L-arginine was significantly more effective than oral at increasing birth weight in IUGR (possibly due to first-pass hepatic metabolism of oral form)
• Optimal dose: <4 g/day (higher doses not more effective; may cause adverse effects via excessive NO)

2023 Cochrane Review (Pels et al., PMID 37428872 - Systematic Review)

• Reviewed all NO-pathway interventions vs. placebo in severe early-onset FGR (<32 weeks)
• Included: sildenafil, tadalafil, L-arginine, nitroglycerin
• For L-arginine specifically: primary mortality outcomes were not reported in included studies, limiting conclusions about hard endpoints
• Moderate-certainty evidence that sildenafil (a PDE5 inhibitor that amplifies NO/cGMP signaling downstream) had little effect on mortality, suggesting NO-pathway alone may not be sufficient in severe FGR
• Highlights that L-arginine evidence is mainly on surrogate outcomes (NO levels, birth weight) rather than perinatal mortality

Practical Points

Summary Diagram

Placental insufficiency
        │
        ▼
↓ Uteroplacental blood flow
↑ ROS / sFLT1
        │
        ▼
eNOS uncoupling → ↓ NO → vasoconstriction → ↑ UA Doppler PI
        │
        ▼
↓ O₂/nutrient delivery → IUGR

L-ARGININE SUPPLEMENTATION
        │
        ▼
↑ eNOS substrate → ↑ NO synthesis
↓ ROS burden (keeps eNOS coupled)
        │
        ▼
↑ cGMP in smooth muscle → vasodilation
↑ Uteroplacental & umbilical blood flow
↑ Angiogenesis (VEGF synergy)
↑ Polyamines → cell proliferation
        │
        ▼
↑ Fetal O₂/nutrient delivery
↑ Birth weight, ↓ SGA risk